泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

已收盘 12-19 16:08:47

32.500

-0.550

-1.66%

最高32.650	最低31.800	成交量77.43万
今开32.500	昨收33.050	日振幅2.57%
总市值281.11亿	流通市值39.98亿	总股本8.65亿
成交额2,499万	换手率0.63%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":32.5,"timestamp":1734595727017,"preClose":33.05,"halted":0,"volume":774300,"delay":0,"floatShares":123000000,"shares":864948570,"eps":2.511245,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.55,"latestTime":"12-19 16:08:47","open":32.5,"high":32.65,"low":31.8,"amount":24986644,"amplitude":0.025719,"askPrice":32.55,"askSize":1000,"bidPrice":32.45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.1887330616320118,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1596729600000,"adjPreClose":33.05,"dividendRate":0.018748,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.999061,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":61.3,"timestamp":1734591813000,"preClose":62.19,"halted":0,"volume":6026873,"delay":0,"premium":"-50.58"}},"requestUrl":"/m/hq/s/03347/wiki","defaultTab":"wiki","newsList":[{"id":"2492172338","title":"港股公告掘金 | 艾美疫苗：第二代高效价吸附破伤风疫苗获得临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2492172338","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492172338?lang=zh_cn&edition=full","pubTime":"2024-12-19 23:03","pubTimestamp":1734620622,"startTime":"0","endTime":"0","summary":"【重大事项】华人置业(00127)附属拟1.62亿英镑出售英国伦敦物业狮腾控股(02562)拟与新加坡艺人管理媒体公司等联合举办真人秀项目《SuperStreamer Asia》艾美疫苗(06660)：第二代高效价吸附破伤风疫苗获得临床试验许可艾美疫苗(06660)：新技术路线悬浮培养四价MDCK细胞流感疫苗获临床试验许可未来数据集团(08229)就发展低空经济业务订立多项战略合作连连数字(025","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1216","06660","159646","BK1583","02562","BK1141","08229","BK1253","YANG","HSCEI","HSTECH","BK1155","03347","BK1576","02598","BK1161","00127","BK1601"],"gpt_icon":1},{"id":"2492912071","title":"艾美疫苗(06660)：第二代高效价吸附破伤风疫苗获得临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2492912071","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492912071?lang=zh_cn&edition=full","pubTime":"2024-12-19 21:27","pubTimestamp":1734614874,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗 公布，该集团第二代高效价吸附破伤风疫苗已于近日获得国家药品监督管理局《药物临床试验批准通知书》，标志着该疫苗的研发进入了新的阶段。破伤风是一种极为严重的潜在致命性疾病，目前接种破伤风疫苗是预防破伤风最经济有效的措施。其中，四联疫苗用于预防百日咳、白喉、破伤风和b型流感嗜血杆菌引起的侵入性感染，具有减少婴幼儿的接种针次，增强家长和婴幼儿接种依从性等优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1583","03347","BK1576","159646","BK1161","06660"],"gpt_icon":0},{"id":"2492045127","title":"第一三共(DSNKY.US)申报的DS-3939a临床试验申请已获得受理  为该产品首次在中国申报临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2492045127","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492045127?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:50","pubTimestamp":1734612635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今日，中国国家药监局药品审评中心官网公示，第一三共申报的1类新药DS-3939a临床试验申请已获得受理。公开资料显示，DS-3939a是一种靶向TA-MUC1的抗体偶联药物，正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询，本次为该产品首次在中国申报临床。体外研究表明，DS-3939a通过DXD介导的细胞毒作用表现出TA-MUC1依赖性的细胞生长抑制作用。此外，DS-3939a在几种TA-MUC1阳性癌细胞系来源的异种移植模型和各种PDX模型中表现出显著的抗肿瘤作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","DSNKY","BK1583","BK4007","BK1576","03347"],"gpt_icon":0},{"id":"2492104121","title":"艾美疫苗：新技术路线悬浮培养四价MDCK细胞流感疫苗获临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2492104121","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492104121?lang=zh_cn&edition=full","pubTime":"2024-12-19 19:49","pubTimestamp":1734608940,"startTime":"0","endTime":"0","summary":"艾美 疫苗 (06660.HK)发布公告，集团新技术路线悬浮培养四价MDCK细胞流感疫苗，已于近日获得国家药品监督管理局《药物临床试验批准通知书》，标志着该疫苗的研发进入了新的阶段。目前，国内上市的流感疫苗均基于鸡胚工艺生产，尚无基于细胞基质的流感疫苗获批上市。MDCK细胞流感疫苗作为重磅大单品，该款产品上市后有望成为集团新的业绩增长点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219200056a1fb1379&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219200056a1fb1379&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1161","BK1141","BK1583","06660","03347"],"gpt_icon":0},{"id":"2492147708","title":"复星医药：控股子公司签署药品合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147708","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147708?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:27","pubTimestamp":1734604032,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","BK1191","BK1593","BK1583","02196","BK0239","03347","BK0188","600196","BK0012","BK1576","BK0196","BK0175","BK0187","BK0028","BK0060","BK0183","BK0096","BK1515","02696","BK1141"],"gpt_icon":0},{"id":"2492314147","title":"艾美疫苗(06660)：新技术路线悬浮培养四价MDCK细胞流感疫苗获临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2492314147","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492314147?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:12","pubTimestamp":1734603162,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾美疫苗 发布公告，集团新技术路线悬浮培养四价MDCK细胞流感疫苗，已于近日获得国家药品监督管理局《药物临床试验批准通知书》，标志着该疫苗的研发进入了新的阶段。MDCK细胞流感疫苗作为重磅大单品，该款产品上市后有望成为集团新的业绩增长点。与传统的鸡胚流感裂解疫苗相比，集团研发的MDCK细胞流感疫苗，在产品质量和安全性方面均得到显著提高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1583","BK1141","BK1161","BK1576","06660"],"gpt_icon":0},{"id":"2492144264","title":"健康元(600380.SH)：JKN2403片获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2492144264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492144264?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:46","pubTimestamp":1734601615,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健康元(600380.SH)公告，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，批准公司的JKN2403片开展临床试验(用于中重度慢性阻塞性肺病)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","BK0046","BK1583","BK0077","600380","BK0114","BK1576","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2492144197","title":"健康元最新公告：公司JKN2403片获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2492144197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492144197?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:40","pubTimestamp":1734601235,"startTime":"0","endTime":"0","summary":"健康元公告，公司近日收到国家药监局签发的《药物临床试验批准通知书》，批准公司JKN2403片开展用于中重度慢性阻塞性肺病的临床试验。JKN2403片是一款公司从海外引进后独立开发的创新口服药物，通过抑制脯氨酰内肽酶（PREP）活性，有效阻止COPD炎症介质的产生，从而控制COPD的急性加重。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900029094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","03347","BK0046","BK1583","BK0077","600380","BK0114","BK1576","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2492141848","title":"华润双鹤最新公告：普瑞巴林缓释片III期临床试验启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2492141848","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492141848?lang=zh_cn&edition=full","pubTime":"2024-12-19 17:11","pubTimestamp":1734599483,"startTime":"0","endTime":"0","summary":"华润双鹤公告，公司全资子公司双鹤利民已启动普瑞巴林缓释片III期临床试验，正式展开受试者招募。该药品主要用于治疗带状疱疹后神经痛及与糖尿病周围神经病变相关的神经性疼痛。普瑞巴林缓释片为原研未进口仿制药，需进行有效性及安全性临床试验才能申报生产，已获得医学伦理委员会批件。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900028377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0239","BK1141","BK1583","BK1576","BK0010","03347","BK0175","BK0028","600062"],"gpt_icon":0},{"id":"2492112663","title":"港股异动 | 同源康医药-B(02410)涨超7%创新高 海外重磅ADC获突破性疗法认定 公司核心产品正进行临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2492112663","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492112663?lang=zh_cn&edition=full","pubTime":"2024-12-19 15:03","pubTimestamp":1734591834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超7%创上市新高，盘中高见50.5港元，较招股价12.1港元已涨超300%。截至发稿，涨6.28%，报49.95港元，成交额1174.21万港元。海通证券指出，Dato-DXd获首个突破性疗法认定，为EGFR突变NSCLC患者带来新希望。招股书显示，同源康医药公司已建立由11款候选药物组成的管线，包括2个低风险产品TY-9591、TY-302，5款创新临床产品，4款处于临床前阶段的产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","BK1576","09939","BK4080","159938","BK1583","BK1161","ADC","BK4231","BK1141","BK1574","03347","BK1515"],"gpt_icon":0},{"id":"2492236164","title":"泰格医药控股子公司为其他控股孙公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2492236164","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492236164?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:20","pubTimestamp":1734567600,"startTime":"0","endTime":"0","summary":"　　泰格医药发布公告，公司控股孙公司合亚医药科技（上海）有限公司因业务发展需要，拟向境内工商银行申请办理总金额不超过人民币500万元的授信业务，用以补充公司经营资金。公司控股子公司方达医药技术（上海）有限公司拟为上述授信业务提供连带责任保证，本次担保金额不超过人民币500万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-19/doc-inczxzyc7068619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03347","LU1820825898.SGD","BK1576","BK1583","LU1146622755.USD","BK1141","BK0028","BK0174","300347","BK0216","BK0077"],"gpt_icon":0},{"id":"2492164383","title":"基石药业(02616.HK)治疗淋巴瘤药物临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2492164383","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492164383?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:14","pubTimestamp":1734567240,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK) 公布，旗下管线2.0重磅产品“CS5001(ROR1ADC)”全球多中心Ib期临床试验完成首例患者入组。据介绍，CS5001是目前已知首个在实体瘤和淋巴瘤中，均观察到临床抗肿瘤疗效的ROR1 ADC，其临床开发进展位于全球前二。临床数据显示，CS5001作为单药治疗侵袭性和惰性晚期淋巴瘤的客观缓解率高于同类竞品，具有快速注册上市及冲击一线联合治疗格局的潜力。另外，CS5001全球多中心试验在美国、澳洲及中国同步进行，目前已推进至Ib期进行剂量优化，后续潜在扩展为II期单臂注册研究。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405109/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02616","03347","BK1576","BK1583","BK1161","BK1141","BK1574"],"gpt_icon":0},{"id":"2492613731","title":"基石药业-B(02616)：CS5001(ROR1 ADC)全球多中心Ib期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2492613731","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492613731?lang=zh_cn&edition=full","pubTime":"2024-12-19 08:08","pubTimestamp":1734566916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司管线2.0重磅产品CS5001全球多中心Ib期临床试验顺利完成首例患者入组。截至目前，CS5001在Ia期10个剂量组的剂量递增试验评估中，已展现出良好的安全性及明显的抗肿瘤活性。此外，在晚期实体瘤中，例如非小细胞肺癌、胰腺癌等，也观察到CS5001明显的疗效信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","ADC","02616","BK1583","BK1574","BK1576","BK1161","BK4231","BK4080"],"gpt_icon":0},{"id":"2492188355","title":"泰格医药(03347)控股子公司为其他控股孙公司提供担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492188355?lang=zh_cn&edition=full","pubTime":"2024-12-18 20:49","pubTimestamp":1734526161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，公司控股孙公司合亚医药科技(上海)有限公司(以下简称“上海合亚”)因业务发展需要，拟向境内工商银行申请办理总金额不超过人民币500万元的授信业务，用以补充公司经营资金。公司控股子公司方达医药技术(上海)有限公司(以下简称“方达上海”)拟为上述授信业务提供连带责任保证，本次担保金额不超过人民币500万元。本次控股子公司方达上海为控股孙公司上海合亚提供担保是为满足其日常业务进一步的发展需要，担保对象为公司合并报表范围内的控股子公司，风险可控，符合公司利益，不会对公司的正常运作和业务发展产生不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0174","BK0216","LU1820825898.SGD","BK1141","BK1583","LU1146622755.USD","BK1576","03347","300347","BK0028"],"gpt_icon":0},{"id":"2492512910","title":"全球唯一拥有猪肾的人，出院了","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512910","media":"医学界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492512910?lang=zh_cn&edition=full","pubTime":"2024-12-18 19:34","pubTimestamp":1734521675,"startTime":"0","endTime":"0","summary":"鲁尼是全球第三位接受基因编辑猪肾移植的人，此前已经顺利出院，目前恢复情况良好。撰文 | 凌骏责编丨汪航昨日，纽约大学朗格尼医学中心宣布，53岁的女子托瓦娜·鲁尼成为目前全球唯一拥有猪肾的人。主刀外科医生表示，她的猪肾功能一切正常。最终，美国FDA批准了这台手术，手术地点定在纽约大学，由完成前一例猪肾移植的蒙哥马利医生，以及洛克医生共同主刀。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.ifeng.com/c/8fQ5Ojx6sxn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK1576","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"2492932908","title":"【港股通】上海医药(02607)拟用于治疗精神分裂症的创新药“I048”临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932908","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932908?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:32","pubTimestamp":1734514347,"startTime":"0","endTime":"0","summary":"金吾财讯 | 上海医药(02607)，集团开发的“I048”临床试验申请收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。该项目由上海医药集团股份有限公司主导研发，公司拥有全球独占实施许可权益。截至目前，该项目已累计投入研发费用为2,516.30万元人民币。截至本公告日，全球未有完全相同靶点和同适应症的药品上市。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MTc4YzRjNTJiOWFmNWRhNjdlMWVhYTgzMTk5OTQyMTM4MDAx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK1576","159992","BK0209","BK0012","03347","BK0028","02607","BK0097","BK1141","HSCEI","BK0188","BK0184","BK0175","BK1583","BK0099","HSTECH","BK1197","06978","YANG","BK1161","BK0183","BK1574","601607","BK0187","BK0020"],"gpt_icon":0},{"id":"2492297714","title":"华东医药(000963.SZ)：HDM1005注射液药品临床试验申请获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2492297714","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492297714?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:28","pubTimestamp":1734514106,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华东医药 发布公告，2024年12月17日，公司全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知，由中美华东申报的HDM1005注射液药品临床试验申请已获得美国FDA批准，可在美国开展I期临床试验。本次HDM1005注射液临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","03347","LU1969619763.USD","BK0187","BK0196","BK1141","BK0132","LU2328871848.SGD","BK1583","000963","BK0209","BK1576","BK0183","BK0188"],"gpt_icon":0},{"id":"2492073972","title":"上海医药：“I048”获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2492073972","media":"证券日报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492073972?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:07","pubTimestamp":1734512853,"startTime":"0","endTime":"0","summary":"证券日报网讯12月18日晚间，上海医药发布公告称，近日，公司开发的“I048”临床试验申请收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412183272159932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1576","BK1583","BK1141","03347","BK1197"],"gpt_icon":0},{"id":"2492725789","title":"上海医药(02607)：“I048 ”获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2492725789","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492725789?lang=zh_cn&edition=full","pubTime":"2024-12-18 17:05","pubTimestamp":1734512707,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，该公司开发的“I048”临床试验申请收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。I048 是小分子一类新药，拟用于治疗精神分裂症。该项目由上海医药集团股份有限公司主导研发，公司拥有全球独占实施许可权益。截至目前，该项目已累计投入研发费用为 2516.30 万元人民币。公司本次申报的“I048”需完成临床试验并经国家药监局批准后方可上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226526.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0020","BK0097","BK0175","BK0028","BK1583","BK0099","BK0209","601607","02607","BK1197","BK0184","BK0187","BK0188","BK0183","03347","BK1141","BK0012","BK0196"],"gpt_icon":0},{"id":"2492724629","title":"恒瑞医药最新公告：子公司获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2492724629","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492724629?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:58","pubTimestamp":1734512290,"startTime":"0","endTime":"0","summary":"恒瑞医药公告称，公司子公司上海恒瑞医药有限公司和上海盛迪医药有限公司收到国家药监局核准签发的关于注射用SHR-1501、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800028699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0188","600276","LU1064130708.USD","LU0405327148.USD","LU1328615791.USD","BK1576","LU1064131003.USD","BK0196","BK0239","BK1583","BK1141","LU0405327494.USD","03347","BK0183","BK0060","LU2488822045.USD","BK0012","BK0028"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.053},{"period":"1month","weight":-0.012},{"period":"3month","weight":0.2425},{"period":"6month","weight":0.1203},{"period":"1year","weight":0.0097},{"period":"ytd","weight":-0.0474}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.100468},{"month":2,"riseRate":0.5,"avgChangeRate":-0.009723},{"month":3,"riseRate":0.75,"avgChangeRate":0.001875},{"month":4,"riseRate":0.25,"avgChangeRate":-0.034639},{"month":5,"riseRate":0.25,"avgChangeRate":-0.024615},{"month":6,"riseRate":0.5,"avgChangeRate":-0.01435},{"month":7,"riseRate":0.5,"avgChangeRate":-0.014965},{"month":8,"riseRate":0,"avgChangeRate":-0.073433},{"month":9,"riseRate":0.4,"avgChangeRate":0.041739},{"month":10,"riseRate":0.4,"avgChangeRate":-0.034537},{"month":11,"riseRate":0.4,"avgChangeRate":0.029037},{"month":12,"riseRate":0.4,"avgChangeRate":0.04691}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}